Stem Cell Mobilization and VEGF Gene Transfer for Heart Failure

Inclusion Criteria: * Be \> 21 years old. * Have mild or moderate (NYHA Class II or III) CHF secondary to ischemic heart disease. * Have left ventricular ejection fraction \<40%. * Patients must have total occlusion of one or more extramural coronary arteries demonstrated by diagnostic angiography within 6 months prior to study enrollment. * Patients must be on a stable cardiac medical regimen (i.e. the same anti-anginal and anti-congestive medications) for 1 month prior to determination of their baseline functional status. The judgment regarding the optimal medical regimen for each individual subject will have been made by the referring cardiologist. * Subjects must be identified as non-candidates for conventional revascularization by their referring cardiologist. * Have serum B-type Natriuretic Peptide (BNP) level \>100 pg/ml. * Women of childbearing potential must agree not to become pregnant during the course of the study. Nonsterile men participating in the study must also agree not to impregnate their partners. * Have the ability to understand the requirements of the study, provide written informed consent, abide by the study restrictions, and agree to return for the required assessments. Exclusion Criteria: * Have a history of alcohol or drug abuse within 3 months of screening. * Subjects with evidence (clinical, laboratory, or imaging) or history of neoplasm, or, cancer recurrence within the past 5 years (other than non-melanoma skin cancer or in situ cervical carcinoma). * Have evidence of moderate to severe proliferative retinopathy on fundoscopic examination by an ophthalmologist. * History of severe aortic stenosis (aortic valve area \< 1.0 cm2) or insufficiency(\>2+); severe mitral stenosis (mitral valve area \<1.5 cm2); or severe mitral insufficiency(\>2+). * Coronary revascularization procedures within 6 months of study enrollment. * Documented stroke or transient ischemic attack (TIA) within 60 days of study enrollment. * Severe co-morbidity associated with a reduction in life expectancy of less than 1 year, such as chronic medical illness (i.e. severe chronic obstructive pulmonary disease, renal failure or cancer). * Joint or peripheral vascular disease that severely limit treadmill walking. * Chronic obstructive pulmonary disease that severely limits walking or FEV1.0\<30% predicted. * Have idiopathic or non-ischemic heart failure. * Have NYHA Class IV heart failure. * Have or require mechanical ventricular support * Had surgical heart failure treatments, including left ventricular reconstructive surgery (Dor procedure, cardiomyoplasty, LV banding, etc.) * Implantation of biventricular pacemaker within 90 days of study treatment. * Be pregnant or lactating. * Have a history of an allergy to penicillin. * Have sickle cell disease. * Have an untreatable coagulopathy. * Have a serum creatinine \>3.5 mg/dL. * Have any clinically significant abnormality in liver function or other clinical chemistry or hematology test (defined as a value more than 2 times the upper limit of the normal range for that value). * Previous enrollment in the study. * Be unsuitable for participation in the study, in the opinion of the Investigator.